Geode Capital Management, LLC Corvus Pharmaceuticals, Inc. Transaction History

Geode Capital Management, LLC

$1.21 Trillion
Q3 2024

A detailed history of Geode Capital Management, LLC transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 563,009 shares of CRVS stock, worth $4.61 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

563,009

Previous 460,140 22.36%

Holding current value

$4.61 Million

Previous $837,000 255.08%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$1.78 - $5.92 $183,106 - $608,984	102,869 Added 22.36%	563,009 $2.97 Million
Q2 2024 Aug 09, 2024	BUY	$1.36 - $2.29 $120,192 - $202,383	88,377 Added 23.77%	460,140 $837,000
Q1 2024 May 13, 2024	BUY	$1.76 - $2.41 $20,034 - $27,433	11,383 Added 3.16%	371,763 $661,000
Q3 2023 Nov 13, 2023	BUY	$1.41 - $2.97 $25,804 - $54,353	18,301 Added 5.35%	360,380 $526,000
Q2 2023 Aug 11, 2023	BUY	$1.0 - $3.86 $44,279 - $170,916	44,279 Added 14.87%	342,079 $783,000
Q4 2022 Feb 13, 2023	SELL	$0.74 - $1.04 $488 - $686	-660 Reduced 0.22%	297,800 $253,000
Q1 2022 May 13, 2022	BUY	$1.46 - $2.48 $19,835 - $33,693	13,586 Added 4.77%	298,460 $489,000
Q4 2021 Feb 11, 2022	BUY	$2.34 - $5.31 $174,636 - $396,290	74,631 Added 35.5%	284,874 $686,000
Q3 2021 Nov 12, 2021	BUY	$1.89 - $8.53 $39,126 - $176,588	20,702 Added 10.92%	210,243 $1.02 Million
Q2 2021 Aug 13, 2021	BUY	$2.46 - $3.14 $100,139 - $127,819	40,707 Added 27.35%	189,541 $506,000
Q1 2021 May 12, 2021	BUY	$2.86 - $4.77 $109,177 - $182,089	38,174 Added 34.5%	148,834 $458,000
Q4 2020 Feb 12, 2021	SELL	$3.56 - $4.86 $3,161 - $4,315	-888 Reduced 0.8%	110,660 $393,000
Q3 2020 Nov 13, 2020	SELL	$2.6 - $5.37 $85,316 - $176,211	-32,814 Reduced 22.73%	111,548 $447,000
Q2 2020 Aug 13, 2020	BUY	$2.01 - $4.05 $10,946 - $22,056	5,446 Added 3.92%	144,362 $392,000
Q1 2020 May 14, 2020	BUY	$1.74 - $5.98 $2,368 - $8,138	1,361 Added 0.99%	138,916 $293,000
Q4 2019 Feb 13, 2020	BUY	$2.56 - $5.44 $20,986 - $44,597	8,198 Added 6.34%	137,555 $748,000
Q3 2019 Nov 12, 2019	BUY	$3.01 - $6.5 $43,834 - $94,659	14,563 Added 12.69%	129,357 $389,000
Q2 2019 Aug 14, 2019	SELL	$3.3 - $4.58 $158,720 - $220,284	-48,097 Reduced 29.53%	114,794 $429,000
Q1 2019 May 14, 2019	BUY	$3.75 - $4.97 $39,487 - $52,334	10,530 Added 6.91%	162,891 $654,000
Q4 2018 Feb 13, 2019	BUY	$3.29 - $8.94 $80,019 - $217,438	24,322 Added 19.0%	152,361 $559,000
Q3 2018 Nov 13, 2018	BUY	$8.58 - $11.4 $40,205 - $53,420	4,686 Added 3.8%	128,039 $1.1 Million
Q2 2018 Aug 14, 2018	BUY	$9.42 - $13.73 $446,423 - $650,678	47,391 Added 62.39%	123,353 $1.35 Million
Q1 2018 May 15, 2018	BUY	$7.48 - $11.53 $14,683 - $22,633	1,963 Added 2.65%	75,962 $875,000
Q4 2017 Feb 13, 2018	BUY	$9.3 - $16.93 $5,821 - $10,598	626 Added 0.85%	73,999 $766,000
Q3 2017 Nov 14, 2017	BUY	$11.3 - $17.23 $51,968 - $79,240	4,599 Added 6.69%	73,373 $1.17 Million
Q2 2017 Aug 14, 2017	BUY	N/A	68,774	68,774 $832,000

Others Institutions Holding CRVS

# of Institutions

Shares Held

30.4M

Call Options Held

1.06M

Put Options Held

84.3K

View Full List

About Corvus Pharmaceuticals, Inc.

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $381M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

More about CRVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Corvus Pharmaceuticals, Inc. Transaction History